Nanosonics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Nanosonics şirketinin toplam hissedar öz sermayesi A$182.2M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$237.3M ve A$55.1M dir. Nanosonics 'in FAVÖK'ü A$8.6M faiz karşılama oranı -2.2 dur. Şirketin A$129.6M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	-2.2x
Nakit	AU$129.55m
Eşitlik	AU$182.20m
Toplam yükümlülükler	AU$55.14m
Toplam varlıklar	AU$237.34m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OQS 'nin kısa vadeli varlıkları ( A$198.4M ) kısa vadeli yükümlülüklerini ( A$32.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: OQS şirketinin kısa vadeli varlıkları ( A$198.4M ) uzun vadeli yükümlülüklerini ( A$22.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OQS borçsuzdur.

Borcun Azaltılması: OQS un 5 yıl önce borcu yoktu.

Borç Kapsamı: OQS un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: OQS şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Nanosonics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Nanosonics Limited Announces Board Retirements

Nanosonics Limited, Annual General Meeting, Nov 12, 2024

Investor sentiment improves as stock rises 22%

Full year 2024 earnings released: EPS: AU$0.043 (vs AU$0.066 in FY 2023)

Nanosonics Limited to Report Fiscal Year 2024 Results on Aug 27, 2024

Independent Non-Executive Director recently sold €185k worth of stock

New minor risk - Insider selling

First half 2024 earnings released: EPS: AU$0.02 (vs AU$0.034 in 1H 2023)

New minor risk - Share price stability

Now 42% undervalued after recent price drop

Nanosonics Limited to Report First Half, 2024 Results on Feb 26, 2024

Now 23% undervalued

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Nanosonics Limited Announces Appointment of Jason Burriss as Chief Financial Officer, Effective 3 October 2023

Nanosonics Limited Appoints Larry Marshall as Non- Executive Director, Effective from 3 October 2023

Now 23% undervalued after recent price drop

Nanosonics Limited, Annual General Meeting, Nov 03, 2023

Full year 2023 earnings released: EPS: AU$0.066 (vs AU$0.012 in FY 2022)

Nanosonics Limited to Report Fiscal Year 2023 Results on Aug 22, 2023

Nanosonics Limited Announces the Appointment of Tracey Batten as Non-Executive Director, Effective 26 September 2023

Nanosonics Announces Company Secretary Changes

Independent Non-Executive Director recently sold €315k worth of stock

First half 2023 earnings released

Nanosonics Limited to Report First Half, 2023 Results on Feb 23, 2023

Insufficient new directors

Insufficient new directors

CEO, President recently sold €671k worth of stock

Now 27% undervalued

Full year 2022 earnings released: EPS: AU$0.012 (vs AU$0.029 in FY 2021)

Nanosonics Limited, Annual General Meeting, Nov 18, 2022

Nanosonics Limited to Report Fiscal Year 2022 Results on Aug 23, 2022

Insufficient new directors

Nanosonics Limited Provides Revenue Guidance for the Fiscal Year 2022

Nanosonics Limited Announces Management Changes

Now 22% undervalued after recent price drop

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Nanosonics Limited to Report First Half, 2022 Results on Feb 22, 2022

Nanosonics Limited Provides Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings released: EPS AU$0.029 (vs AU$0.034 in FY 2020)

Nanosonics to Launch Digital Platform for Infection Control

Revenue misses expectations

First half 2021 earnings released: EPS AU$0.005 (vs AU$0.019 in 1H 2020)

New 90-day low: €3.84

Nanosonics Limited to Report First Half, 2021 Results on Feb 24, 2021

New 90-day high: €5.05

New 90-day high: €4.16

New 90-day high: €4.06

I-MED Signs Agreement with Nanosonics to Upgrade Their Trophon EPR Fleet to Trophon2

Nanosonics Limited Do Not Provide Earnings Guidance for the Fiscal Year 2021

Full year earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin